β-1.3-1.6 glucan (Aureobasidium medium)

Details β-1.3-1.6 glucan (Aureobasidium medium) β-1.3-1.6 glucan (Aureobasidium medium)

2005-10-18

2005-10-18

Wilson, James O. (Department: 1623)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C536S063000, C536S123100, C424S070100, C424S070130, C424S401000, C424S439000, C424S440000, C424S442000, C514S054000, C426S648000, C426S656000, C426S658000, C435S091500, C435S074000, C435S101000, C435S102000

Reexamination Certificate

active

06956120

ABSTRACT:
Aureobasidiumβ-1,3-1,6 glucans and compositions containing such glucans, as well as methods of their preparation.Aureobasidiummedium that contains β-1,3-1,6 glucans, particularly medium produced byAureobasidiumstrain FERM P-18099. The β-glucans of the present invention have a variety of industrial and commercial uses, including applications in pharmaceutical or medical products or treatments, for the removal or control of environmental or microbiological contaminants, in cosmetics, and in nutritional products and foods.

REFERENCES:
patent: 5789579 (1998-08-01), Fujii et al.
patent: 62205008 (1987-09-01), None
patent: 06146036 (1994-05-01), None
patent: 06340701 (1994-12-01), None
Finkelman, Malcolm A. J. et al., “Synthesis of Beta-glucan by cell-free extracts ofAureobasidium pullulans,” Canadian Journal of Microbiology, 1987, 33 (2), 123-127.
Hamada, Nobutake et al., “The Structure of the Carbohydrate Moiety of an Acidic Polysaccharide Produced byAureobasidiumsp. K-1,” Agric. Biol. Chem, 1983, 47 (6), 1167-1172.
Abel et al., “Stimulation of Human Monocyte β-Glucan Receptors by Glucan Particles Induces Production of TNF-α and IL-1β,” Int. J. Immunopharmacology, vol. 14, No. 8, 1992, pp. 1363-1373.
Czop et al., “Isolation and Characterization of β-Glucan Receptors on Human Mononuclear Phagocytes,” J. Exp. Med., vol. 173, Jun. 1991, pp. 1511-1520.
Czop et al., “Phagocytosis of Particulate Activators of the Human Alternative Complement Pathway Through Monocyte β-Glucan Receptors,” Biochemistry of the Acute Allergic Reations: Fifth International Symposium, Jun. 20-21, 1988, pp. 287-296.
Di Renzo et al., “The function of human Nk cells is enhanced by β-gulcan, a ligand of CR3 (CD11b/CD18)*,” Eur. J. Immunol., 1992, 21, pp. 1755-1758.
Elstad et al., “CD11b/CD18 Integrin and a β-glucan Receptor Act in Concert to Induce the Synthesis of Platelet-Activating Factor by Monocytes1,” J. Immunol. vol. 152, 1994, pp. 220-230.
Hetland et al., “Protectived Effect of β-Glucan Against Mycobacterium bovis, BCG Infection in BALB/c Mice,” Scand. J. Immunol., 47, 1998, pp. 548-553.
Jespersgaard et al., “Protective Immunity againstStreptococcus mutansInfection in Mice after Intranasal Immunization with the Glucan-Binging Region of S. mutans Glucosyltransferase,” Infection and Immunity, vol. 67, No. 12, Dec. 1999, pp. 6543-6549.
Kay et al., “Enhancement of human monocyte β-glucan receptors by glucocorticoids,” Immunology, 81, 1994, pp. 96-102.Ross et al., “Specificity of Membrane Complement Receptor Type Three (CR3) for β-Glucans1,” Complement 4, 1987, pp. 61-74.
Komatsu et al., “Host-Mediated Antitumor Action of Schizophylian, A Glucan Produced by Schizophyllum Commune,” GANN, 60, Apr. 1969, pp. 137-144.
McLeish et al., “Bacterial phagocytosis activates extracellular signal-regulated kinase and p38 mitogen-activated protein kinase cascades in human neutrophils,” Journal of Leukocyte Biology, vol. 64, Dec. 1998, pp. 835-844.
Moerk et al., “Effects of particulate and soluble (1-3)-β-glucans on Ca2+ Influx in NR8383 alveolar macrophages,” Immunopharmacology 40, 1998, pp. 77-89.
Nobutake, Kobunshi Kako. (Polymer Applications), Kobunshi Kankokai., vol. 36, No. 5, 1987, pp. 9-16.
Ol et al., “Structural Studies on “Isosclerotan”, a New Glucan Isolated from Sclerotinia Fungus, by Physical, Chemical and Enzymatic Methods,” Agr. Biol. Chem., vol. 30, No. 3, 1966, pp. 266-273.
Patchen et al., “Glucan-Induced Hemopoietic and Immune Stimulation: Therapeutic Effects in Sublethally and Lethally Irradiated Mice,” Meth and Find Expti Clin Pharmacolo, 1986, 8(3), pp. 151-155.
Poutsiaka et al., “Cross-Linking of the β-Glucan Receptor on Human Monocytes Results in Interleukin-1 Receptor Antagonist But Not Interleukin-1 Production,” Blood, vol. 82, No. 12, Dec. 15, 1993, pp. 3695-3700.
Ross et al., “Therapeutic intervention with complement and β-glucan in cancer,” Immunopharmacology 42, 1999, pp. 61-74.
Ross et al., “Specificity of Membrane Complement Receptor Type Three (CR3) for β-Glucans1,” Complement 4, 1987, pp. 61-74.
Singh et al., “Scleroglucan, an antitumor polysaccharide from Scierotium glucanicum,” Carbohydrate Research, 37, 1974, pp. 245-247.
Smiley, “Microbial Polysaccharides—A Review,” Food Technology, Sep. 1966, pp. 112-116.
Szczesniak et al., “Objective Characterization of the Mouthfeel of Gum Solutions,” Journal of Food Science, vol. 27, No. 4, Jul.-Aug. 1962, pp. 381-385.
Teramoto, “Markedly increased plasma (1-3) β-glucan is a diagnostic and therapeutic indicator of Pneumocystis carinii pneumonla in a non-AIDS patient,” Journal of Medical Microbiology, vol. 49, 2000, pp. 393-394.
Thornton et al., “Analysis of the Sugar Specificity and Molecular Location of the β-Glucan-Binding Lectin Site of Complement Receptor Type 3 (CD11b/SC18),” J. Immunol., vol. 156, 1996, pp. 1235-1246.
Wakshull et al., “PGG-Glucan, a soluble β-(1,3)-glucan, enhances the oxidative burst response, microbicidal activity, and activates an NF-kB-like factor in human PMN: Evidence for a glycosphingolipid β-(1,3)-glucan receptor,” Immunopharmacology 41, 1999, pp. 89-107.
Xia et al., “Generation of Recombinant Fragments of CD11b Expressing the Functional β-Glucan-Binding Lectin Site of CR3 (CD11b/CD18)1,” J. Immunol. vol. 162, 1999, pp. 7285-7293.
Xia et al., “The β-Glucan-Binding Lectin Site of Mouse CR3 (CD11b/CD18) and its Function in Generating a Primed State of the Receptor That Mediated Cytotoxic Activation in Response to iC3b-Opsonized Target Cells1,” The American Association of Immunologists, 1999, pp. 2281-2290.
Yan et al., “β-Glucan, a “Specific” Biologic Response Modifier That Uses Antibodies to Target Tumors for Cytotoxic Recognition by Leukocyte Complement Receptor Type 3 (CD11 b/CD18)1, ” J. Immunol., vol. 163, 1999, pp. 3045-3052.
Yoshioka et al., “Immunotoxicity of soluble β-glucans induced by indomethacin treatment,” FEMS Immunology and Medical Microbiology, 21, 1998, pp. 171-179.

Affiliated with

Also associated with

Rating

β-1.3-1.6 glucan (Aureobasidium medium) does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with β-1.3-1.6 glucan (Aureobasidium medium), we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β-1.3-1.6 glucan (Aureobasidium medium) will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3470271